-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KOS-1803 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. KOS-1803 in Solid Tumor Drug Details: KOS-1803 (Iso-Fludelone) is under development for the treatment of...
-
Product Insights
Sendai-Ko Biomass Power Project
Sendai-Ko Biomass Power Project is a biopower project located in Miyagi, Japan. The project is owned and developed by Sendai-ko Biomass Power GK. The project is currently under construction. Empower your strategies with our Sendai-Ko Biomass Power Project report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the report...
-
Product Insights
NewNet Present Value Model: Kura Oncology Inc’s KO-539
Empower your strategies with our Net Present Value Model: Kura Oncology Inc's KO-539 report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KO-2806 in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KO-2806 in Colorectal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KO-2806 in Colorectal Cancer Drug Details: KO-2806 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KO-2806 in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KO-2806 in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KO-2806 in Pancreatic Ductal Adenocarcinoma Drug Details: KO-2806 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KO-2806 in Metastatic Renal Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KO-2806 in Metastatic Renal Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KO-2806 in Metastatic Renal Cell Carcinoma Drug Details: KO-2806 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ziftomenib in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ziftomenib in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ziftomenib in Acute Myelocytic Leukemia (AML,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ziftomenib in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ziftomenib in Refractory Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ziftomenib in Refractory Acute Myeloid Leukemia Drug Details: Ziftomenib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ziftomenib in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ziftomenib in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ziftomenib in Relapsed Acute Myeloid Leukemia Drug Details: Ziftomenib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – KO-2806 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - KO-2806 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. KO-2806 in Non-Small Cell Lung Cancer Drug Details: KO-2806 is...